Clinical Trials Directory

Trials / Completed

CompletedNCT04115800

Liposomal Sirolimus in Dry Eye Disease

Subconjunctival Treatment of Liposomal Sirolimus as a Treatment for Dry Eye Disease

Status
Completed
Phase
EARLY_Phase 1
Study type
Interventional
Enrollment
52 (actual)
Sponsor
Instituto de Oftalmología Fundación Conde de Valenciana · Academic / Other
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

Dry eye disease is a very frequent pathology that importantly affects the quality of life of patients; in spite of the common use of eye lubricants to ameliorate symptoms, there is still a large number of patients who do not present improvement of the disease or they worsen. Although its etiology is varied, the imbalance of the immune system plays a substantial role in the development of dry eye disease. Rapamycin or sirolimus is an anti-inflammatory and immunomodulatory drug that has an enormous potential in ocular surface pathologies such as dry eye disease. The aim of the present study is to determine the effectiveness and security of subconjunctival application of a new formulated drug of liposomal sirolimus in patients with moderate and severe dry eye disease. This is a randomized placebo-controlled double blind clinical trial. Patients presenting data of moderate or severe dry eye disease will be randomized into two groups. One group will receive additional to the conventional treatment, subconjunctival injections of liposomal sirolimus; meanwhile the other group will receive subconjunctival placebo injections. After intervention the effectiveness and the security of the liposomal sirolimus will be evaluated.

Conditions

Interventions

TypeNameDescription
DRUGLiposomal SirolimusSubconjunctival injections of liposomal sirolimus in patients with conventional treatment with moderate and severe dry deye disease

Timeline

Start date
2019-10-02
Primary completion
2020-05-01
Completion
2020-08-01
First posted
2019-10-04
Last updated
2021-02-10

Locations

1 site across 1 country: Mexico

Source: ClinicalTrials.gov record NCT04115800. Inclusion in this directory is not an endorsement.